Sign inJoin waitlistJoin the waitlist

WT

William Tew

Clinical Director, Gynecologic Medical Oncology Service · New York Presbyterian Hospital

Credentials: · · · ·

History

Gynecologic Medical Oncology Service · New York Presbyterian Hospital
Present

Weill Cornell Medical College
2004–2005
Memorial Sloan Kettering Cancer Center
2002–2004
New York University Medical Center
1999–2002
University of Rochester School of Medicine and Dentistry
1995–1999

Research

Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study
Journal of Clinical Oncology · 2011 · Last of 16 authors · 1,394 citations
Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology
Journal of Clinical Oncology · 2018 · 1,176 citations
Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults With Cancer
Journal of Clinical Oncology · 2016 · Last of 17 authors · 478 citations

CA
Carol Aghajanian
42 papers
Dennis Chi
38 papers
RO
Roisin O'Cearbhaill
36 papers
Stuart Lichtman
34 papers
Arti Hurria
31 papers
JK
Jason Konner
30 papers
YS
Yukio Sonoda
29 papers
Heidi Klepin
28 papers · 2 as a resident
NA
Nadeem Abu-Rustum
27 papers
Supriya Mohile
27 papers
RG
Rachel Grisham
26 papers
Cary Gross
24 papers · 3 as a resident

Clinical trials

Geriatric Assessment and Nursing Telephone Intervention in Elderly Women With Ovarian Cancer
Principal investigator · Completed
Memorial Sloan Kettering Cancer Center
2011–2025
Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Principal investigator · Completed · Phase 2
GOG Foundation
2010–2015
Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission
Principal investigator · Terminated · Phase 2
Memorial Sloan Kettering Cancer Center
2007–2008
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Principal investigator · Completed · Phase 1
Regeneron Pharmaceuticals
2004